SkinBioTherapeutics Reports Quadrupled Revenue in FY25 Trading Update

SkinBioTherapeutics just dropped its FY25 trading update, and the numbers make for seriously interesting reading. Let’s unpack what this means for the company, its strategy, and investors.

Headline Grabber: Revenue Quadruples, Losses Narrow Dramatically

The standout figures are impossible to ignore:

• Revenue Surge: Expected unaudited revenue of £4.5m-£4.8m, a massive jump from £1.2m in FY24. That’s roughly 4x growth year-on-year. While slightly below market hopes of £5.1m, the reason is purely timing – significant orders landed just *after* the June year-end.
• Path to Profitability: The unaudited adjusted EBITDA loss is expected to be just £0.2m-£0.4m, a dramatic improvement from the £2.2m loss in FY24. This screams “careful cost control” alongside rapid revenue scaling.
• Cash Cushion: Year-end cash sits at a healthy £4.8m, comfortably beating expectations (£4.1m). This strength comes courtesy of a successful £4.2m (gross) placing and retail offer completed in June.

Driving the Growth Engine: Acquisitions & Core Products

So, where did this explosive growth come from? Management points to three key drivers:

1. Dermatonics: A full year’s contribution from this acquisition.
2. Bio-Tech Solutions (BTS): Eight months of trading adding to the top line (and noted as having a “strong” July post-year-end).
3. AxisBiotix: Ongoing organic growth from their flagship food supplement line.

This clearly validates their dual strategy: developing innovative in-house products (AxisBiotix) *and* acquiring complementary businesses (Dermatonics, BTS) to accelerate revenue and gain distribution muscle.

The Superdrug Catalyst: Cash Deployment & Autumn Launch

That £4.2m cash raise wasn’t just about bolstering the balance sheet. It was strategically earmarked to fuel the exclusive commercial agreement with Superdrug. This is arguably the most exciting near-term catalyst:

• Costs related to the impending Superdrug launch of AxisBiotix™ food supplements have already started hitting the P&L.
• The team confirms they are “busy preparing” and crucially, “on track” for the launch in Superdrug stores this Autumn. Getting a major national retailer like Superdrug on board is a huge validation and opens up massive high-street consumer reach.

CEO’s Take: A Transformative Year

Stuart Ashman, the CEO, didn’t hold back on the significance: “The past 12 months have marked a distinct change in the operations of the Company.” He highlights:

• The shift from an R&D focus five years ago to a commercially driven business today.
• The quadrupling of revenue and significantly reduced losses.
• The strong cash position enabling growth.
• Fundamental market trends: Increasing consumer and marketplace interest in the skin microbiome plays directly into SkinBioTherapeutics’ core expertise and product portfolio. Ashman believes this positions them perfectly for rapid scaling and shareholder value creation.

Why This RNS Matters for Investors

Beyond the impressive numbers, this update signals several crucial things:

• Commercial Execution: They are successfully integrating acquisitions (Dermatonics, BTS) and driving organic growth (AxisBiotix).
• Financial Inflection Point: Nearing EBITDA profitability with vastly improved cash flow dynamics is a major milestone.
• Major Retail Partnership: The Superdrug deal isn’t just a contract; it’s a potential game-changer for AxisBiotix brand visibility and sales volume. The successful fundraise specifically for this launch shows investor confidence.
• Positive Momentum: The mention of a “strong July” across the board, particularly for BTS, suggests the growth trajectory continues post-year-end.

The slight revenue miss versus expectations seems well-explained by order timing and is more than offset by the better-than-expected cash position and the sheer scale of growth achieved. The focus now shifts sharply to the Autumn launch in Superdrug – execution there will be key to maintaining this impressive momentum. SkinBioTherapeutics appears to be transitioning decisively from a promising science story to a commercially executing growth company. One to watch closely as the Superdrug chapter unfolds.